I-Mab Stock Price, News & Analysis

I-Mab (NASDAQ: IMAB) announced a strategic transformation to become a global biotech platform renamed NovaBridge Biosciences, with a planned Hong Kong IPO for a dual listing on NASDAQ and HKEX. Shareholder approval for the name change is expected at an EGM on October 24, 2025. The company will form a subsidiary, Visara, to acquire VIS-101 (also ASKG712), a VEGF-A/ANG2 bifunctional biologic completing Phase 2 and anticipated to be Phase 3-ready in 2026. Visara will launch with an approximately $37M capital infusion; Transactions are cross-conditioned and expected to close later this month. Kyler Lei is appointed CFO effective Oct 16, 2025.

I-Mab (NASDAQ:IMAB) announced that an abstract with updated Phase 1 givastomig monotherapy data in heavily pre-treated gastroesophageal carcinoma (GEC) patients was accepted as a short-talk at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, Oct 22-26, 2025 in Boston.

The presentation, titled Updated Safety, Efficacy and Biomarker Analysis from the Phase I Study of Givastomig, will be given by Samuel J. Klempner, MD on Thursday, October 23, 2025, 6:20–6:35 PM ET (Presentation B016, Hynes Convention Center).

The company said the Phase 1b dose expansion is fully enrolled and the data support a Phase 2 randomized strategy to combine givastomig with standard of care in first-line GEC across a broad range of Claudin 18.2 expression levels.

I-Mab (NASDAQ: IMAB) announced significant expansion of its givastomig program, a CLDN18.2 x 4-1BB bispecific antibody for cancer treatment. The company plans to initiate a global randomized Phase 2 study in Q1 2026 for first-line metastatic gastric cancers, combining givastomig with immunochemotherapy.

Key developments include Phase 1b dose expansion data expected in Q1 2026, expansion into additional cancer types including biliary tract cancer (BTC) and pancreatic ductal adenocarcinoma (PDAC), and new investigator-initiated trials in neoadjuvant settings. The company also announced leadership changes, with Wei Fu appointed as Executive Chairman and Dr. Sean Cao joining as Chief Business Development Officer.

I-Mab (NASDAQ:IMAB), a U.S.-based global biotech company focused on immuno-oncology, has announced significant leadership enhancements. The company appointed three new independent directors to its Board: Dr. Robert Lenz, a veteran R&D leader from Neumora Therapeutics, Ms. Xin Liu, an Investment Director at Hony Capital, and Dr. Sean Cao, an Operating Partner at CBC Group.

The company has formed a new Research and Development Committee, chaired by Dr. Lenz, to accelerate innovation and growth. Additionally, Dr. Ken Takeshita, Global Head of R&D at Daiichi Sankyo, has been appointed to I-Mab's Scientific Advisory Board. These appointments strengthen I-Mab's leadership as it advances its givastomig program and focuses on R&D excellence.

I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company specializing in precision immuno-oncology agents, has announced its participation in two major investor conferences in September 2025.

The company will attend the Cantor Global Healthcare Conference from September 3-5, 2025, participating in one-on-one meetings. Additionally, I-Mab will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 9:30 AM ET, which will include both a company presentation and one-on-one meetings. The presentation webcast will be available on I-Mab's website for 90 days.

I-Mab (NASDAQ: IMAB) reported Q2 2025 financial results and business updates, highlighting significant progress in its oncology pipeline. The company's lead drug givastomig showed promising Phase 1b results with an 83% objective response rate in combination with immunochemotherapy for first-line gastric cancers.

I-Mab strengthened its financial position through an underwritten offering raising $61.2 million, resulting in a pro-forma cash balance of $226.8 million as of June 30, 2025. This funding is expected to sustain operations through Q4 2028. The company reported reduced R&D expenses of $3.3 million for Q2 2025, down from $5.2 million in Q2 2024, and a net loss of $5.5 million for Q2 2025.

Key upcoming milestones include topline data from givastomig's Phase 1b dose expansion study expected in Q1 2026. The company also acquired Bridge Health, strengthening its intellectual property portfolio for givastomig.

I-Mab (NASDAQ: IMAB) has completed enrollment in its Phase 1b dose expansion study for givastomig, a bispecific Claudin 18.2 x 4-1BB antibody, combined with nivolumab and mFOLFOX6 for first-line treatment of CLDN18.2-positive gastric cancers. The study enrolled 40 patients across two doses (8 mg/kg and 12 mg/kg) in the U.S.

Earlier dose escalation data presented at ESMO GI 2025 showed promising results with an 83% objective response rate (10/12 patients) at the selected doses. The treatment demonstrated rapid and durable responses with favorable safety profiles. Topline results from the expansion study are expected in Q1 2026.

Everest Medicines has announced a strategic US$30.9 million equity investment in I-Mab (NASDAQ: IMAB), which will result in a 16.1% ownership stake. The investment is part of I-Mab's broader US$65 million underwritten offering of American Depositary Shares at $1.95 per ADS.

The investment strengthens the partnership between both companies, leveraging I-Mab's promising oncology pipeline, including givastomig, which showed an impressive 83% overall response rate in Phase 1b trials for first-line gastric cancer. The collaboration aims to combine Everest's mRNA cancer vaccines and CAR-T platform with I-Mab's 4-1BB bispecific antibody pipeline, while utilizing their complementary clinical development capabilities in Asia and the U.S.

I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company, has announced the pricing of an underwritten offering of 33,333,334 American Depositary Shares (ADSs) at $1.95 per ADS, aiming to raise approximately $65 million in gross proceeds.

The offering, expected to close on August 5, 2025, includes participation from notable investors such as Everest Medicines, Janus Henderson Investors, Adage Capital Partners LP, and Exome Asset Management. The proceeds will primarily fund the clinical development of pipeline products, including a randomized Phase 2 trial of givastomig, a bispecific Claudin 18.2 x 4-1BB antibody, targeting progression-free survival data by end of 2027.